MYC  or  BCL2  copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma

Ting-Xun Lu; Lei Fan; Li Wang; Jia-Zhu Wu; Kou-Rong Miao; Jin-Hua Liang; Qi-Xing Gong; Zhen Wang; Ken H. Young; Wei Xu; Zhi-Hong Zhang; Jian-Yong Li

doi:10.18632/oncotarget.4073

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma

Ting-Xun Lu _, Lei Fan, Li Wang, Jia-Zhu Wu, Kou-Rong Miao, Jin-Hua Liang, Qi-Xing Gong, Zhen Wang, Ken H. Young, Wei Xu, Zhi-Hong Zhang and Jian-Yong Li

PDF | HTML | How to cite

Oncotarget. 2015; 6:18374-18388. https://doi.org/10.18632/oncotarget.4073

Metrics: PDF 2249 views | HTML 3038 views | ?

Abstract

Ting-Xun Lu1, Lei Fan1, Li Wang1, Jia-Zhu Wu1, Kou-Rong Miao1, Jin-Hua Liang1, Qi-Xing Gong2, Zhen Wang2, Ken H. Young3, Wei Xu1, Zhi-Hong Zhang2, Jian-Yong Li1,4

1Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

2Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China

Correspondence to:

Jian-Yong Li, e-mail: [email protected]

Keywords: MYC, BCL2, copy number aberration, diffuse large B-cell lymphoma, pathology

Received: February 27, 2015 Accepted: May 18, 2015 Published: May 29, 2015

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). Patients with DLBCL harboring MYC aberrations concurrent with BCL2 or/and BCL6 aberrations constitute a specific group with extremely poor outcome. In this study, we retrospectively investigated the incidence and prognosis of MYC, BCL2, and BCL6 aberrations with DLBCL patients in Chinese population. We applied fluorescence in situ hybridization and immunohistochemical analysis in 246 DLBCL patients. The results showed that patients with MYC or BCL2 copy number aberration (CNA) had significantly worse overall survival (OS) and progression-free survival (PFS) than negative cases (P < 0.0001). Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression). By multivariate analysis, MYC CNA, BCL2 CNA and double CNA were the independent worse prognostic factors. In conclusions, patients with MYC or BCL2 CNA constituted a unique group with extremely poor outcome and may require more aggressive treatment regimens.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4073

Publication Alerts

Research Papers:

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma

Abstract